Seeking Alpha

Elanco Receives FDA Approval for Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), the Broadest(i) Canine Oral Parasiticide Protection ...

GREENFIELD, Ind., Oct. 7, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (ELAN) today announced the U.S. Food and Drug Administration (FDA) has approved Credelio Quattro™ (lotilaner, ...
Seeking Alpha

Elanco Innovation Builds Momentum, Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Reaches Blockbuster Status

Credelio Quattro marked $100 million in net sales making it Elanco's fastest pet health blockbuster in history and one of the industry's fastest ever, especially with a single geographic approval ...
abc27

Now Available: Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Provides Broadest[i] Parasite Protection of Its Kind

"Today is a historic day as we bring veterinarians and pet owners peace of mind with the broadest i parasite protection of its kind for dogs," said Bobby Modi, Executive Vice President, U.S. Pet ...
FiercePharma

Merck KGaA names winner of storytelling competition to boost schistosomiasis awareness in Ethiopia

After nearly two decades spent working with the World Health Organization (WHO) to supply billions of praziquantel tablets to help treat schistosomiasis, Merck KGaA has recently tacked on an ...
Nasdaq

Elanco Receives FDA Approval for Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), the Broadest(i) Canine Oral Parasiticide Protection ...

Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is the first and only canine oral parasiticide to protect against six parasites, including fleas, ticks, ...